ESEF — Europäische Jahresabschlüsse (iXBRL) fact · reporting period
Hyloris Pharmaceuticals: cashflow_financing
One fact, its scope and the complete path back to the official record.
Reported value
-168.000k{"amount": -168000.0, "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities"}- Entity
- Hyloris Pharmaceuticals
- Metric
- cashflow_financing
- Period
- 2024-01-01 – 2024-12-31
- Status
- current
- Source
- ESEF — Europäische Jahresabschlüsse (iXBRL)
Provenance
Official reference
esef:875500LZIWS7QEQE0I73:2024-12-31Source licensePublic filings (ESEF-Verordnung)
Retrieved2026-08-23T23:00:05.269801+02:00
Raw response SHA-256
6b0bf6727f9aa9c456f9be7cc3a10fe9…History
- supersedes {"amount": -420000.0, "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities"} (evidence esef:875500LZIWS7QEQE0I73:2025-12-31)
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.